Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
Form 144 notice for Astera Labs, Inc. (ALAB) reporting a proposed sale of 150,000 common shares through Morgan Stanley Smith Barney on 09/02/2025 on NASDAQ. The filing lists an aggregate market value of $27,330,000 for the block and reports total shares outstanding of 166,219,140. The shares were acquired 03/21/2018 in a private acquisition from the issuer and paid in cash. The filing also discloses multiple Rule 10b5-1 sales by related trusts and entities in the past three months totaling 237,100 shares for gross proceeds of $22,136,140.67. The notice includes the standard attestation that the seller is not aware of undisclosed material adverse information.
Astera Labs (ALAB) submitted a Form 144 notifying the market of a proposed sale of 170,000 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $30,974,000 and an approximate sale date of 09/02/2025. The shares were acquired in a private issuance from the issuer on 03/21/2018 and were paid for in cash. The filing shows total shares outstanding of 166,219,140, and discloses multiple recent Rule 10b5-1 sales by related trusts between 06/20/2025 and 07/21/2025, with individual gross proceeds listed for each transaction. The signer certifies no undisclosed material adverse information and references reliance on planned trading instructions where applicable.
Astera Labs director Jack R. Lazar reported automatic sales of common stock under a Rule 10b5-1 trading plan adopted May 28, 2025. On 08/27/2025 the Form 4 shows five sale transactions totaling 22,500 shares sold in multiple trades at weighted-average prices ranging from about $176.73 to $183.09. The filing lists the reporter's beneficial ownership following the reported sales as 97,351 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/28/2025 and includes footnotes disclosing price ranges for each grouped sale.
Astera Labs, Inc. (ALAB) Form 144 summary: Philip Mazzara filed a notice to sell 20,000 common shares via Morgan Stanley Smith Barney LLC, with an aggregate market value of $3,584,000 and an approximate sale date of 08/28/2025. The shares were acquired on 03/14/2022 through previously exercised stock options and were paid for in cash. The filing reports 166,219,140 shares outstanding for the issuer. It also records a prior sale by the same person of 7,237 shares on 08/18/2025 for gross proceeds of $1,328,064.80. The filer certifies they are not aware of any undisclosed material adverse information about the issuer.
Astera Labs, Inc. (ALAB) submitted a Form 144 notice reporting a proposed sale of 22,500 shares of common stock through UBS Financial Services Inc. on the NASDAQ with an aggregate market value of $4,014,398.25. The filing lists the securities to be sold on 08/27/2025.
The filing shows all 22,500 shares were acquired by the seller through RSU vesting on four dates: 11/15/2024 (2,187), 02/15/2025 (3,438), 05/15/2025 (8,437), and 08/15/2025 (8,438), which together equal the 22,500 shares proposed for sale. The filer reports nothing to report for securities sold in the past three months. The form includes the required signature attestation about absence of undisclosed material adverse information.
Mohan Jitendra, listed as Chief Executive Officer and a director of Astera Labs, Inc. (ALAB), reported an insider transaction dated 08/20/2025. The filing shows a bona fide gift of 150,000 shares of common stock (transaction code G) transferred at a price of $0 to a non‑affiliated entity. Following the reported transactions, the Form 4 lists total indirect beneficial ownership of 4,130,002 shares held across multiple trusts and estate planning vehicles and several other indirect holdings noted in the filing. The Form 4 was signed by an attorney‑in‑fact, Philip Mazzara, on 08/21/2025.
Gajendra Sanjay, President and COO and a director of Astera Labs, Inc. (ALAB), reported automatic sales on 08/18/2025 to satisfy tax withholding related to the vesting and settlement of previously granted restricted stock units. The reporting shows two automated sell-to-cover transactions totaling 91,441 shares sold at weighted average prices of $183.8342 and $183.1698. These sales were mandated by an issuer election and are described as non-discretionary. After the transactions the filing lists 2,215,428 and 2,170,877 shares reported as directly owned (per line items), and additional indirect holdings through estate planning trusts totaling 6,915,545 shares across three trusts. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
Astera Labs insider Philip Mazzara, the company's General Counsel and Secretary, reported sales of company common stock on 08/18/2025. The sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units and were not discretionary trades. The filing shows two grouped sales: 3,710 shares at a weighted average price of $183.8344 and 3,527 shares at a weighted average price of $183.1696, with per-share sale price ranges disclosed in each footnote. The reported post-transaction beneficial ownership balances are 175,100 and 171,573 shares respectively as shown on the form.
Astera Labs (ALAB) director and CEO Mohan Jitendra reported sales of common stock equal to 91,441 shares on 08/18/2025 at weighted-average prices near $183.8 and $183.17 per share. These sales were automatic "sell-to-cover" transactions to satisfy tax withholding on vested restricted stock units and were not discretionary trades by the reporting person. After the transactions the reporting person directly owned 2,170,877 shares. The filing also discloses multiple pools of indirectly owned shares held in various trusts and a living trust, each of which the reporting person disclaims beneficial ownership of except for any pecuniary interest.
Michael Truett Tate, Chief Financial Officer and Director of Astera Labs, Inc. (ALAB), reported routine insider transactions on Form 4. On 08/18/2025 he had automatic "sell-to-cover" sales of restricted stock units to satisfy tax withholding, selling 9,668 shares at a weighted-average price of $183.8343 and 9,193 shares at a weighted-average price of $183.1692. After those sales his direct beneficial ownership totals reported are 268,705 and 259,512 shares respectively. On 08/19/2025 he transferred 55,785 shares to the Tate 1997 Living Trust for no consideration and reported corresponding entries showing 203,727 shares held directly and 457,281 shares indirectly by the trust. The filing notes the transfers were non-discretionary sell-to-cover and the trustee disclaims beneficial ownership except for any pecuniary interest.